• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

Friday, 23 April 2021 / Published in Medical Device, News, NMPA Registration in China

First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

On April 19, the Guangdong MPA (Medical Products Administration) announced the first approved drug product and medical device arriving at the University of Hong Kong – Shenzhen Hospital (HKU-SZH). The drug is an Anti-D (Rho) immunoglobulin injection product and the medical device is a magnetically controlled growing titanium rod. Both products have already been delivered to the HKU-SZH on April 16 for clinical use.

This is a major breakthrough since the Greater Bay Area initiative (currently known as the 港澳药械通 policy in Chinese) was announced by the Chinese and Hong Kong governments to permit the use of Hong Kong-registered drugs and medical devices in designated Hong Kong-owned healthcare institutions in the Greater Bay Area – without prior NMPA registration.

In addition, 54 imported new drugs and medical devices from Hong Kong were selected by the HKU-SZH (reported by Shenzhen Daily on March 24, 2021), and are currently being reviewed by the Guangdong MPA for approval. According to Dr. Lo Chung-mau, the chief executive of the HKU-SZH, the medical devices cover orthopaedic, cardiovascular and surgical products and are selected based on the following factors:

  • Products urgently needed for clinical use
  • Products cannot be substituted in China
  • Products featuring functionalities better than the currently existing products in China to treat patients

Dr. Lo Chung-mau also indicated that the 54 imported products could be accessible in the HKU-SZH as soon as June 2021.

The details of the 54 products or how they were selected has not yet been revealed but it is an interesting development in the Greater Bay Area regulatory pathway.

Cisema recently held a webinar with where we discussed the Greater Bay Area pathway in more detail. You are invited to watch the recording here.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Greater Bay Area

What you can read next

Hong Kong drug and medical device registrations
Hong Kong drug and medical device registrations: Latest updates including China GBA pathways | Upcoming Webinar
China medical device registration electronic certificates
China medical device registration electronic certificates – Full implementation
China medical device quality
China medical device quality and safety responsibilities – New requirements proposed

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP